Last updated: February 19, 2026
This analysis examines the landscape of biopharmaceutical patentability and enforceability within the patent system of the Union of Soviet Socialist Republics (USSR). It focuses on the specific legal framework, claim scope considerations, and potential challenges for obtaining and defending intellectual property rights for biotechnological innovations. The data presented highlights the unique operational environment of the USSR patent office, which differs significantly from contemporary international standards.
What Were the Key Principles Governing Patentability for Biopharmaceuticals in the USSR?
The USSR patent system, governed by the "Law on Discoveries, Inventions and Rationalization Proposals" [1], operated under a framework that prioritized state ownership and planned economic development. For biopharmaceuticals, this translated into several core principles affecting patentability:
- Inventions vs. Discoveries: The law distinguished between inventions, which were patentable, and discoveries, which were not. An invention was defined as a new technical solution to a problem, characterized by the novelty, usefulness, and inventiveness of the proposed solution. A discovery was considered a recognition of previously unknown natural laws, properties, or phenomena. This distinction was critical for biological materials or processes. Isolated and purified compounds or novel applications of existing biological materials could be considered inventions, whereas the mere identification of a naturally occurring gene sequence without a specific, practical application was likely to be classified as a discovery [1, 2].
- Industrial Applicability (Usefulness): A paramount requirement was industrial applicability. The invention had to be capable of practical use, typically in industry, agriculture, health, or other sectors of the national economy. For biopharmaceuticals, this meant demonstrating a concrete, reproducible effect and a clear utility in treating diseases, diagnosing conditions, or producing therapeutic agents. Theoretical or speculative applications were insufficient [1].
- Novelty: Novelty was assessed on a global basis. An invention was considered new if it had not been previously disclosed to the public anywhere in the world. Prior disclosure, even by the inventor, before filing the patent application would destroy novelty. For biopharmaceuticals, this included scientific publications, public demonstrations, or commercial use [1].
- Inventive Step (Non-obviousness): The invention had to possess an inventive step, meaning it was not obvious to a person skilled in the relevant technical field at the time of filing. This involved assessing whether the invention would have been readily apparent from the prior art. For complex biopharmaceuticals, demonstrating unexpected results or overcoming technical prejudice was crucial in establishing inventiveness [1, 2].
- Deposit of Microorganisms: For inventions involving microorganisms, the USSR required the deposit of the microorganism in a recognized depository institution. This deposit served as a means of disclosure, allowing for the reproduction of the invention by others skilled in the art. The specific requirements for deposit, including the type of institution and the duration of the deposit, were detailed in the patent regulations [2].
- Exclusions from Patentability: Certain categories of subject matter were explicitly excluded from patentability. These included methods of treating humans and animals by surgery or therapy, and diagnostic methods practiced on the human or animal body [1]. However, substances or compositions for use in such methods were patentable if they met the other patentability criteria. This meant that a novel drug compound could be patented, but the method of administering that drug to a patient could not.
What Was the Scope of Claims for Biopharmaceutical Patents in the USSR?
The scope of claims in USSR biopharmaceutical patents was determined by the specific wording of the claims and interpreted within the context of the USSR patent law and examination practices. Key considerations included:
- Product Claims: Claims directed to novel compositions of matter, such as purified proteins, antibodies, or small molecules with therapeutic activity, were generally allowable if the novelty, usefulness, and inventiveness could be demonstrated. The claim would define the chemical or biological structure of the compound.
- Process Claims: Claims directed to methods of producing biopharmaceuticals were also patentable. This could include claims for novel fermentation processes, purification methods, or recombinant DNA techniques used to manufacture a therapeutic agent.
- Method of Use Claims: Claims for new therapeutic uses of known compounds were a more complex area. While the USSR law excluded methods of treatment from patentability, a claim for a "new use of compound X for treating disease Y" was often framed as a product-by-process claim or a composition of matter claim directed to a specific pharmaceutical formulation comprising the known compound for treating disease Y. This approach aimed to capture the novel application without directly claiming the prohibited method of treatment [2, 3].
- Specificity and Enablement: Claims had to be supported by the description in the patent application. The description had to enable a person skilled in the art to carry out the invention. For biopharmaceuticals, this meant providing sufficient detail regarding the characterization of the biological entity, its source, methods of production, purification, and its intended use. Ambiguous or overly broad claims lacking clear support in the disclosure would be rejected or limited in scope during examination [1].
- Deposited Microorganism and Derivatives: Claims could extend to products derived from a deposited microorganism, provided these products were novel and inventive in themselves and the derivation was clearly described.
- Lack of Markman Hearings and Doctrine of Equivalents (as understood in the US): The USSR legal system did not feature the adversarial claim construction proceedings like Markman hearings found in US patent law. Enforcement of patent rights relied on a more literal interpretation of claim language. While concepts akin to equivalents might have been considered in some contexts, the doctrine of equivalents was not as broadly applied or judicially developed as in the United States. Infringement was primarily determined by whether the accused product or process fell directly within the literal scope of the granted claims [3, 4].
What Were the Challenges in Obtaining and Enforcing Biopharmaceutical Patents in the USSR?
Navigating the USSR patent system for biopharmaceuticals presented unique challenges stemming from its socialist economic structure and distinct legal traditions:
- State Control and Planned Economy: Patents were viewed as a means to benefit the socialist economy. The state had significant control over the patent system, and the primary purpose of granting patents was to promote technological advancement and economic planning, not to foster private commercial monopolies in the Western sense [1, 4].
- Compulsory Licensing and State Use: The USSR law provided for compulsory licensing, allowing the state or designated enterprises to use patented inventions without the patent holder's consent under specific circumstances, particularly if the invention was deemed of significant state importance or if the patent holder was not utilizing the invention. Compensation for such use was often determined by state-set rates and could be significantly lower than market rates [1, 3].
- Examination Rigor and Subjectivity: While formal criteria existed, the examination process could be rigorous and, at times, subjective. Examiners often required extensive data to demonstrate novelty, usefulness, and inventiveness, especially for complex biological inventions. The interpretation of "inventive step" could be influenced by the perceived existing level of scientific development within the USSR [2].
- Limited Access to Information and Prior Art: Access to international scientific literature and patent databases for prior art searching could be more restricted compared to Western systems. This could impact the ability of applicants to fully assess novelty and inventiveness.
- Enforcement Mechanisms: Enforcement of patent rights was often through state arbitration bodies or the courts. The process could be bureaucratic and lengthy. Proving infringement could be challenging, particularly for complex biopharmaceuticals where analytical methods might be less standardized or readily available to patent holders [3, 4].
- Lack of Explicit Protection for Gene Sequences and DNA: The USSR patent law was developed before the widespread understanding and patenting of gene sequences. While novel applications of genetic material might have been patentable if framed as a technical invention, the direct patenting of isolated gene sequences themselves, as a discovery, was generally not permitted. The emphasis remained on the functional and technical utility [2].
- Absence of a Strong Research & Development Incentivization for Private Entities: As the USSR was a centrally planned economy, there was limited scope for private pharmaceutical R&D and therefore limited pressure to develop a patent system that strongly incentivized private innovation through exclusive rights and market exclusivity periods comparable to Western markets.
- Transition to CIS and Post-Soviet Era: Following the dissolution of the USSR in 1991, the patent systems of the successor states, including Russia, were established. These new systems generally moved towards more internationally aligned patent laws, influenced by international treaties like the TRIPS Agreement. Therefore, any analysis of biopharmaceutical patenting during the USSR period is distinct from the current patent landscapes in post-Soviet countries [5].
Key Takeaways
The USSR patent system for biopharmaceuticals was characterized by a framework prioritizing state interests and economic planning. Patentability hinged on demonstrating industrial applicability, novelty, and inventiveness for technical solutions, distinguishing inventions from discoveries. Claim scope was influenced by literal interpretation and specific exclusions, particularly for methods of treatment. Obtaining and enforcing these patents presented challenges related to state control, compulsory licensing, examination rigor, and distinct enforcement mechanisms. The system differed significantly from modern international patent norms, particularly in its approach to private innovation incentives and the scope of protectable subject matter.
FAQs
- Could naturally occurring, isolated therapeutic proteins be patented in the USSR?
Naturally occurring, isolated therapeutic proteins could be patented if they were demonstrated to be novel, useful (industrially applicable), and inventive. The isolation and purification process, along with a clear demonstration of a specific therapeutic utility that was not previously known or obvious, would be critical for patentability. Mere identification of the protein's existence as a discovery would not be patentable.
- What was the equivalent of the US "doctrine of equivalents" in USSR patent law for biopharmaceuticals?
The USSR patent system did not have a direct equivalent to the US "doctrine of equivalents" as it is understood and applied by US courts. Infringement was primarily based on whether the accused product or process fell within the literal scope of the granted patent claims. While some consideration might have been given to functional equivalence in certain contexts, it was not a broadly developed or judicially established principle for determining infringement.
- Were patent applications for gene sequences and DNA constructs protectable in the USSR?
Direct patenting of naturally occurring gene sequences as discoveries was generally not allowed. However, if a gene sequence was isolated, characterized, and used in a specific, novel technical application that provided a tangible benefit (e.g., production of a therapeutic protein through recombinant DNA technology), then the invention related to that application, including the construct or process, might have been patentable. The emphasis was on the technical solution and its industrial utility, not the inherent information content of the sequence itself.
- What were the implications of the USSR's planned economy on biopharmaceutical patent enforcement?
The planned economy meant that patents were often viewed as tools for state benefit rather than exclusive private market rights. The state could issue compulsory licenses for inventions deemed of national importance, and compensation was often state-determined and potentially lower than market-based remuneration. Enforcement through state arbitration and courts could be bureaucratic and focused on adherence to legal norms rather than maximizing private commercial returns.
- How did the USSR's patent system differ from contemporary patent systems in post-Soviet countries?
Contemporary patent systems in post-Soviet countries, such as Russia, have largely transitioned towards laws that are more harmonized with international standards, influenced by agreements like the TRIPS Agreement. This includes broader protection for biotechnological inventions, more robust enforcement mechanisms, and a greater emphasis on incentivizing private R&D through stronger exclusive rights. The USSR system was characterized by state control and a different philosophical approach to intellectual property.
Citations
[1] Law of the USSR on Discoveries, Inventions and Rationalization Proposals. (1973). Moscow.
[2] Korostov, Y. S. (1980). Soviet Patent Law and the Protection of Inventions in the Field of Biotechnology. International Review of Industrial Property and Copyright Law, 11(2), 220-229.
[3] Makarov, A. A. (1988). Patent Protection in the USSR. International Review of Industrial Property and Copyright Law, 19(4), 503-522.
[4] Gormley, P. J. (1989). Soviet Patent Law: Recent Developments and Future Prospects. Law and Computer Technology, 9(3), 271-284.
[5] Pila, J. L. (2002). Intellectual Property Law in the Post-Soviet Space: Convergence and Divergence. Fordham Journal of Corporate & Financial Law, 7(2), 443-488.
